The Latest Cardiac and Vascular News
NeuroVascular Quality Initiative Quality Outcomes Database (NVQI-QOD) Celebrates 25,000th Procedure Milestone FAIRFAX, Va.– The Society of NeuroInterventional Surgery’s (SNIS) Patient Safety Organization (PSO), in partnership with the NeuroPoint Alliance (NPA), is pleased to announce that the NVQI-QOD has recorded more than 25,000 procedures in the registry. This significant milestone underscores […]
CHILLICOTHE, Ohio, Nov. 19, 2024 /PRNewswire/ — When something doesn’t feel right, you need expert care that’s close to home. Adena Health understands this, and that is why the experts with the Adena Heart and Vascular Institute and Adena Orthopedic and Spine Institute strive to deliver…
PASADENA, Calif., Nov. 19, 2024 /PRNewswire/ — Huntington Medical Research Institutes (HMRI), a pioneer in scientific research with a track record of groundbreaking discoveries, announced promising breakthroughs in the treatment of stroke at the American Heart Association (AHA)…
NEW YORK, Nov. 19, 2024 /PRNewswire/ — Remedy Pharmaceuticals, a leader in stroke drug development, announced today that a Type C meeting held with the U.S. Food and Drug Administration (FDA) on October 16, 2024, provided valuable feedback on the design of a Phase 3 trial of its…
Recognized as innovative biopharma developing a potentially safer and superior anticoagulant for patients with implanted cardiac devices and rare cardiovascular conditions PONTE VEDRA, Fla., Nov. 19, 2024 /PRNewswire/ — Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a late-stage…
VAPI, India, Nov. 19, 2024 /PRNewswire/ — Meril, a global leader in cutting-edge cardiovascular and structural heart solutions, is renowned for its next-generation transcatheter heart valve technologies. Upholding its commitment to innovation, Meril continues to drive advancements in…
Delivering on commitments, executing ahead of expectations, and raising guidance Innovation driving sustained growth across many franchises: TAVR, PFA, Leadless Pacemakers, Diabetes, Spine, and Neuromodulation GALWAY, Ireland, Nov. 19, 2024 /PRNewswire/ — Medtronic plc (NYSE: MDT) today…
ROME, Nov. 19, 2024 /PRNewswire/ — A comprehensive study led by Professor Dr. Achille Gaspardone was presented at the 2024 TCT Congress which, demonstrated the exceptional efficacy of the Noblestitch™ suture-mediated Patent Foramen Ovale (PFO) closure system in preventing recurrent…
Muvalaplin, an oral, once-daily treatment that inhibits lipoprotein(a) formation via a novel mechanism, achieved positive results in a 12-week Phase 2 study These data were published in the Journal of the American Medical Association (JAMA) and simultaneously presented today at the…
– Acoramidis demonstrated the earliest known time to separation in cardiovascular outcomes in the ATTRibute-CM study (3 months), with statistically significant risk reduction of 36% on All-Cause Mortality (ACM) alone at Month 36 within the Open Label Extension
